Should we have compulsory measles vaccination at school entry?
Current measles vaccination policy might not give high enough coverage to prevent its resurgence Related items fromOnMedica Parental confidence in immunisation programme ‘very high’ Adjuvanted trivalent flu vaccine best option for over-65s Texting can improve flu jab uptake Most CCGs missing smoking target for pregnant women Type 2 diabetes in 10 times more young people than realised
Conclusion: FN made in the 4:3:3 ratio of powder of corn, powder of bean cake defatted and powder of peeled whole potato is more effective to decrease the levels of postprandial 2h-blood glucose. FN is a staple type of functional food that could be used for the treatment of IGT.
To what extent does male alcohol consumption impact a couple's time to pregnancy?Human Reproduction
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its investigational CD20xCD3 T-cell engaging bispecific mosunetuzumab has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies.“We are pleased that the FDA has granted Breakthrough Therapy Designation to mosunetuzumab, recognising the promising early efficacy data for this molecule and the remaining unmet need in follicular lymphoma,” said Levi Gar...
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Authors: Couturier A, Giocanti-Auregan A, Massin P Abstract Initial management of diabetic macular edema (DME) is well-defined, but there is a lack of national or international consensus for patients who do not respond or respond only partially to these treatments. Several studies, mostly retrospective, have assessed medication switches, but currently, the literature contains no randomized studies. The goal of this article is to present an algorithm for switching medications, which can be proposed to DME patients treated with anti-VEGF agents, as defined by a group of French retina experts, supported by the existin...
A new study examines the predictive value of signal intensities of MRI T1 mapping in Graves'ophthalmopathy patients with refractory diplopia.Clinical Endocrinology
Senior administration officials involved in Operation Warp Speed said Monday treatments could be shown effective before a vaccine.